Missed that PR...thanks.
SANTA ANA, Calif. – February 27, 2015 – Iteris, Inc. (NYSE MKT: ITI), a leader in providing intelligent traffic management and weather information solutions, has entered into an agreement with AgRenaissance Software LLC to integrate Iteris’ ClearAg™ Select high-resolution, field-level weather information into AgRenaissance’s FieldX™ suite of software for agricultural producers, agronomists and applicators.
Iteris’ ClearAg solution provides agribusinesses with actionable field-level weather and soil information needed for the data-driven decision making required for efficient crop management, resource allocation, and risk reduction and mitigation. ClearAg is a series of application programming interfaces (API’s) and mobile application products that can be readily integrated with third-party agricultural software applications like FieldX from AgRenaissance. FieldX is an easy-to-use, record-keeping tool for agricultural producers, agronomists and applicators. The FieldX suite includes PC software, an iPad® app, and a cloud-based data storage system.
“Through the integration of ClearAg field-level weather technology, we believe AgRenaissance customers will be able to make accurate, real-time decisions around scouting and other field operations,” said Tom Blair, senior vice president of iPerform at Iteris. “We are committed to providing our partners and customers with high-resolution, field-level weather, soil and crop analytics that drive productivity and enhanced value. Our agreement with AgRenaissance and other customers confirms the value proposition of our ClearAg product offering, as well as our strategy to unlock the true potential of our Big Data analytics capabilities for precision ag applications.”
“We look forward to integrating Iteris’ ClearAg Select solution into our FieldX suite of precision ag tools,” said David Krueger, president and CEO of AgRenaissance. “We see great value in providing our customers timely and accurate precision weather information to help them enhance crop management decisions, crop production planning, and record-keeping.”
You did alright with your first stock. I paid around $300 for 100 shares of my first stock, 30 years ago. Last time I checked it was worth $100. The certificate is still around here somewhere?
Agree, if they deliver on revenue I can see the price double over the next couple of years. Awesome move...to uplist to NYSE in U.S.. Makes the company legit for institutional investors in America.
Yes, very positive presentation. 2015 is going to be a fun year for Orbcomm investors. We're just starting to see the pieces of the puzzle mesh together for a much stronger growth vehicle...over the coming years!
I don't know, it seems like more to it than he's tired and wants a change. Hope we hear more about the reason he retired over the coming weeks. As far as a new CEO, Iteris should be a great choice for a technology leader. Lots of talent to choose from.
I don't have a clue. No sign or hint of it on the conference call. The old CFO didn't stay long and missed his mark. Iteris spent a lot cleaning up the legal stuff. I could see where several suitors would see value in their products & sector though.
Sounds like more of the same...which is a good thing when extending contracts. I expect we'll hear more about this on the conference call.
Seems you jumped the gun selling and may be one reason it dropped as far as it did. Must be something bigger in the works we don't know about?
There's one of the reasons this is my #1 stock for the last few years.
"ORBCOMM and Komatsu Sign Renewed Services Agreement
Extends 14-year relationship of delivering world-class heavy equipment telematics solutions."
Sure didn't see this coming. He's one of my favorite CEOs and took good care of Iteris. Can't wait to find out why? As much as Abbas was taking the company to a new level...the company is in a perfect position to take advantage of their connection to consumer's vehicles...sort of like apple!!! Could be with all of the cash, BOD wanted a quarterly dividend. I've had two of my microcaps start this new trend. Could be a merger or buyout, but I would've stayed on for that. Thanks Abbas and hope you do well in your future.
Good deal, glad it worked out and you're welcome. Also a positive that Norsat was responsive. Nsat's management seems to be in a promote the company & stock mode. They release earnings mid next week, so hoping there is growth.
Now, as you can see, I am projecting a significant 20% increase in sales from 2014 to 2015. To arrive at this, I discounted the total sales of my 2014 projections by 4% due to possible risk effects, such as changes in defense spending, delayed orders, competition, etc. I then added $15.2 million, representing sales from the company's acquisitions of Eur-Pac, AMK, and Woodbine, bringing the total revenue estimate to $75,899,000.
The following graph shows the breakdown of Air Industries' projected revenue for 2015, showing the sizable impact that its new acquisitions will have on revenue growth.
Air Industries carries a notable amount of risk for the following reasons:
•Its market capitalization sits below $70 million, making it a microcap company. These stocks are often susceptible to high volatility.
•The company is in an extremely competitive space with many larger, heavy-hitting corporations.
•Air Industries is heavily reliant on defense contracts, therefore any reductions in government defense spending (or more specifically, military aviation) can have a significant negative impact on the company.
12-Month Return Projection
Air Industries has been trading at a price-to-sales ratio of 1.1, which I believe will continue through 2015. With projected revenue exceeding $75 million, at a P/S ratio of 1.1, Air Industries should hit around $12 per share for the year 2015. I believe that to be a conservative estimate, considering the increase in anticipated revenue growth. The industry P/S ratio averages 1.4 - such a ratio would place Air Industries stock price at $15 per share, a 52% increase.
My 12-month projection for Air Industries is $12.75 per share; an increase of $2.82 per share from its current price of $9.93, or a 34% total return including its dividend of 6.04%. This estimate contains a P/S ratio just below 1.2, which I believe to be a fair estimate with regard to investors' reaction to increasing revenue, a continued acquisition strategy, and the ability to capitalize on the growing commercial aerospace industry.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
I think that's an awesome buy. You'll be paid 6-7% annual interest with dividends. I'd add more myself, but Air is already a top 5 holding.
"Monday, February 23, 2015, 10:34am CST
Medtronic buys maker of device for overactive bladders"
Medtronic paid an undisclosed amount to acquire Advanced Uro-Solutions, which makes a device that treats overactive bladder.
Elizabethton, Tenn.-based Advanced Uro-Solutions' NURO system technology uses electrical pulses to stimulate nerves that control bladder function. But unlike many Medtronic devices, Advanced Uro-Solutions' system isn't implanted inside the body, and instead uses an external stimulator.
The deal closed in December, Medtronic said Monday. Medtronic plans to launch NURO, which is approved by the Food and Drug Administration, within the next 12 months.
Advanced Uro-Solutions' device will compete with Minnetonka-based Uroplasty Inc.'s Urgent PC, which has been on the U.S. market for several years. Uroplasty announced in December it would merge with Vision-Sciences Inc. to create a new company called Cogentix Medical Inc. That deal is expected to close later this year.
"The acquisition of Advanced Uro-Solutions expands Medtronic`s portfolio of treatment options for those suffering from chronic symptoms of overactive bladder," said Linnea Burman, vice president and general manager, gastro-urology therapies at Medtronic, in a news release. "Medtronic continues to invest in fully implantable bladder control and bowel control therapies, and the addition of the NURO system to our existing portfolio of products will introduce more people suffering from bladder control issues to the benefits of neuromodulation."
Most likely has something to do with the new New York listing. A call to broker should straighten it out for both of you. Low volume stocks like this require long term goals as you know, both to sell and buy. GL
My cost is $9.99/trade for NYSE shares. Not sure if you're buying TSE exchange shares and fees might be different? You could also use "all or nothing limit orders"...but bottom line your broker should lower the commission or time to switch. Ameritrade is great, I've had no problem with higher fees on any stocks, including sub $.01 stocks.
Good article. I've been preaching this for over a decade. Maybe the public will finally demand the extra safety.
"So, if the risk is significant and the fix is so intuitive and simple, why aren’t doctors adopting the newer system? We believe there are two connected reasons. The first reason is reluctance to change the way they are accustomed to performing the procedures. Doctors are creatures of habit, and they conduct the same procedure the same way for years.
The second reason is that doctors and hospitals may worry that buying new sheath-compatible equipment and a new maintenance contract will be very expensive, even though the system is a lot more cost-effective than what they currently have. Using sheaths means less time cleaning the endoscopes and more patients that can be serviced. Finally, patients just don’t know the infection risk of these so-called “routine” procedures. Patients assume that the equipment their doctors use is sterile and that their procedures are too commonplace to worry about. But there is no such thing as a routine medical procedure that has a routine risk of life threatening infection.
Even though using a sheathed scope during any procedure is the best protection you can get, you’re probably not going to get it. More stringent policies are required to get doctors to adopt newer scopes with sheaths. The next best thing is for patients to step up and ask what kind of scope their doctor is using before their procedure, and insist on sheathed scopes. If you don’t, the next time you’re in a doctor’s waiting room for a colonoscopy or any other scope procedure, take a look to your left and to your right. Chances are you may be sharing more than just a scope with all the people in the room with you."
The more I think about it, UPI share price should be double on this news. Safety and law suits should force the use of disposable endosheaths. The local news here in NC is talking about this incident. I watched a guy lowest on the totem pole, clean a cystoscope. I assume he did it correctly, but there are several steps that have to be done perfectly. These folks are being pulled from every direction and time to clean the devices is not their only priority.